WAM
NKTR icon

Wealthspire Advisors (Maryland)’s Nektar Therapeutics NKTR Stock Holding History

Wealthspire Advisors (Maryland)’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-29
Closed -$15K – 1459
2019
Q1 		$15K Hold
29
– – ﹤0.01% 1387
2018
Q4 		$14K Buy
29
+13
+81% +$7.85K ﹤0.01% 1346
2018
Q3 		$15K Buy
16
+2
+14% +$1.71K ﹤0.01% 1409
2018
Q2 		$10K Buy
14
+4
+40% +$4.61K ﹤0.01% 1546
2018
Q1 		$15K Sell
10
-7
-41% -$9.02K ﹤0.01% 1405
2017
Q4 		$16K Buy
17
+15
+750% +$8.87K ﹤0.01% 1404
2017
Q3 		$1K Buy
+2
New +$626 ﹤0.01% 2119

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Wealthspire Advisors (Maryland)'s NKTR Position: Q2 2019 in Review

Wealthspire Advisors (Maryland) sold out of Nektar Therapeutics (NKTR) in Q2 2019, closing a stake of 29 shares — an estimated $15K sold.

Wealthspire Advisors (Maryland) first reported a position in NKTR in Q3 2017 and held it in 7 quarters. The position peaked at $16K in Q4 2017. 336 funds tracked by Wall St. Rank hold NKTR as of Q2 2019.

  • Wealthspire Advisors (Maryland) reported no remaining Nektar Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Wealthspire Advisors (Maryland) sold 29 Nektar Therapeutics shares in Q2 2019, an estimated $15K.
  • Wealthspire Advisors (Maryland) first reported a position in Nektar Therapeutics in Q3 2017 and held it in 7 quarters.
  • Wealthspire Advisors (Maryland)'s Nektar Therapeutics position peaked at $16K in Q4 2017.
  • 336 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2019.

Based on Wealthspire Advisors (Maryland)'s 13F filing for Q2 2019, filed 12 Aug 2019.